• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Unilife, Amgen extend negotiations a 3rd time

Unilife, Amgen extend negotiations a 3rd time

February 16, 2016 By Fink Densford

Unilife, AmgenUnilife (NSDQ:UNIS) and Amgen (NSDQ:AMGN) are tacking on another 11 days to come to an agreement on whether their deal for Unilife’s wearable injector technology will be exclusive to Amgen or not.

The extension makes the 3rd in the past month for the companies, as they gave themselves another week last Monday to settle the deal. Two weeks prior, York, Pa.-based Unilife said the companies agreed to extend the deadline on the exclusivity negotiations from Jan. 31 to Feb. 5. Amgen is based in Thousand Oaks, Calif.

UNIS shares jumped last month after the companies revealed the initial deal, which called for a non-refundable $15 million deposit from Amgen, which will use Unilife’s wearable injector devices for some of its large-volume drug products. The deal also included a perpetual exclusive license for Unilife’s 1mL wearable injector for use with Amgen’s small-volume drug products.

The new deadline gives the companies until a minute before midnight on February 26, according to an SEC filing for Unilife. As it stands now, Unilife will still develop most of the injectors, with Amgen footing the bill for each device manufactured for its use. If Unilife can’t keep up production, Amgen will be able to source the manufacturing elsewhere, with a 10% royalty going to Unilife. The deal also included a caveat which will allow Amgen to source 20% of their annual volume elsewhere, with Unilife receiving the difference per unit between their price and the manufacturing and procurement cost.

The deal was good news for Unilife, which last October said it tapped chairman & CEO Alan Shortall for a loan so it could avoid defaulting on its $60 million debt with OrbiMed.

Unilife, which slashed 17% from its workforce in September, said earlier that month that it’s exploring the proverbial “strategic alternatives.” In October, the company said it’s “received interest” from several parties.

Unilife shares are down approximately 11.5% in mid-day trading, at 94¢ per share as of 12:53 p.m. EST.

Filed Under: Business/Financial News, Pharmaceutical, Wall Street Beat Tagged With: Amgen, Unilife Corp.

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy